We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$337M
AUM Growth
+$3.84M
Cap. Flow
-$22.8M
Cap. Flow %
-6.78%
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$9.48M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.12M
3
CAH icon
Cardinal Health
CAH
+$6.74M
4
AGN
Allergan plc
AGN
+$5.18M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.64M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.87M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
CFNL
Cardinal Financial Corp
CFNL
+$5.03M
5
FRX
FOREST LABORATORIES INC
FRX
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
2 Financials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
51
Supernus Pharmaceuticals
SUPN
$2.77B
$2.49M 0.74%
227,000
+30,463
+15% +$271K
ARIA
52
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.48M 0.74%
390,000
+152,190
+64% +$1.05M
THOR
53
DELISTED
THORATEC CORPORATION
THOR
$2.35M 0.7%
67,500
-1,288
-2% -$42.9K
IDIX
54
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$2.34M 0.69%
+97,100
New +$1.01M
ZBH icon
55
Zimmer Biomet
ZBH
$18.4B
$2.34M 0.69%
+23,175
New +$2.26M
CFN
56
DELISTED
CAREFUSION CORPORATION
CFN
$2.22M 0.66%
50,000
+10,692
+27% +$442K
NPSP
57
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.21M 0.66%
67,000
-99,970
-60% -$2.89M
AFL icon
58
Aflac
AFL
$62.6B
$2.21M 0.66%
+71,000
New +$2.22M
BCR
59
DELISTED
CR Bard Inc.
BCR
$2.15M 0.64%
+15,000
New +$2.14M
COR icon
60
Cencora
COR
$61.2B
$2.07M 0.61%
28,500
-6,500
-19% -$445K
MASI
61
DELISTED
Masimo
MASI
$2.05M 0.61%
87,000
+23,125
+36% +$574K
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$1.97M 0.58%
122,835
– –
OCR
63
DELISTED
OMNICARE INC
OCR
$1.9M 0.56%
28,500
-10,808
-27% -$672K
RAD
64
DELISTED
Rite Aid Corporation
RAD
$1.86M 0.55%
13,000
-4,240
-25% -$626K
OREX
65
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.85M 0.55%
30,020
-2,900
-9% -$169K
HOLX
66
DELISTED
Hologic
HOLX
$1.85M 0.55%
+73,000
New +$1.71M
HPTX
67
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.84M 0.55%
70,369
-3,333
-5% -$85.7K
CERN
68
DELISTED
Cerner Corp
CERN
$1.8M 0.54%
+35,000
New +$1.84M
AMGN icon
69
Amgen
AMGN
$222B
$1.78M 0.53%
15,000
-31,135
-67% -$3.6M
MD icon
70
Pediatrix Medical
MD
$2.2B
$1.75M 0.52%
+30,000
New +$1.77M
TSRO
71
DELISTED
TESARO, Inc.
TSRO
$1.71M 0.51%
+55,000
New +$1.47M
CPHD
72
DELISTED
Cepheid Inc
CPHD
$1.68M 0.5%
35,000
-4,308
-11% -$195K
ITCI
73
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.66M 0.49%
98,269
– –
ARRY
74
DELISTED
Array Biopharma Inc
ARRY
$1.5M 0.45%
329,199
– –
INFI
75
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.44M 0.43%
113,273
-19,493
-15% -$203K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $22.8M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.

  • Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
  • Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
  • Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
  • Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.